Brokerages Set Achieve Life Sciences, Inc. (NASDAQ:ACHV) Target Price at $14.80

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) has been given an average rating of "Buy" by the six research firms that are currently covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $14.80.

A number of brokerages have weighed in on ACHV. Raymond James initiated coverage on Achieve Life Sciences in a report on Friday, September 27th. They issued a "strong-buy" rating and a $20.00 target price on the stock. Oppenheimer reiterated an "outperform" rating and issued a $11.00 target price on shares of Achieve Life Sciences in a research report on Thursday, August 15th. Rodman & Renshaw started coverage on shares of Achieve Life Sciences in a report on Thursday. They issued a "buy" rating and a $12.00 target price for the company. Finally, RODMAN&RENSHAW raised shares of Achieve Life Sciences to a "strong-buy" rating in a report on Thursday.

Achieve Life Sciences Price Performance

Shares of NASDAQ:ACHV traded down $0.14 during trading on Friday, reaching $4.25. 196,823 shares of the company traded hands, compared to its average volume of 140,272. The company has a quick ratio of 6.78, a current ratio of 6.78 and a debt-to-equity ratio of 0.31. Achieve Life Sciences has a 52 week low of $3.03 and a 52 week high of $5.98. The firm has a market capitalization of $146.16 million, a PE ratio of -3.76 and a beta of 1.57. The company's 50 day moving average is $4.72 and its two-hundred day moving average is $4.76.

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.10). During the same quarter in the previous year, the company earned ($0.34) EPS. As a group, sell-side analysts predict that Achieve Life Sciences will post -1.17 earnings per share for the current year.

Institutional Investors Weigh In On Achieve Life Sciences

Hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new position in shares of Achieve Life Sciences during the third quarter valued at $54,000. Virtu Financial LLC bought a new position in shares of Achieve Life Sciences during the first quarter valued at $59,000. The Manufacturers Life Insurance Company bought a new position in shares of Achieve Life Sciences during the second quarter valued at $69,000. MetLife Investment Management LLC raised its stake in shares of Achieve Life Sciences by 65.6% during the third quarter. MetLife Investment Management LLC now owns 14,993 shares of the biopharmaceutical company's stock valued at $71,000 after acquiring an additional 5,939 shares during the last quarter. Finally, Verition Fund Management LLC bought a new position in shares of Achieve Life Sciences during the third quarter valued at $113,000. 33.52% of the stock is currently owned by institutional investors and hedge funds.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.